- Contribution to the development of a bio-venture ecosystem through creation of a large-scale Biotech
- Promotion of domestic pharmaceutical companies' business portfolio conversion and opportunities to enhance international competitiveness
- Realize drug-discovery technology and development products hidden inside pharmaceutical companies as a strategy conversion and promote open innovation through strengthening external cooperation
Our Portfolio
SCOHIA PHARMA, Inc.
| Outline | R&D, manufacturing and sales of medical products |
|---|---|
| Website | |
| Industry | Health/medicine |
| Commercialization stage | Venture company |
Provided Support
| Authorized Investment | 10 billion JPY (INCJ 70.5%, Takeda 19.5%, MEDIPAL HD 10.0%) |
|---|---|
| Announcement Date | Mar 14, 2017 |
| Investment Structure |